DayOne | October 23, 2021
DayOne, the Healthcare Innovation initiative based in Switzerland, announces the extended deadline for the global call for its digital health accelerator to Friday, 5 November 2021.
Startups with a focus on pain therapy can apply to be considered for the DayOne Accelerator by 5 November 2021. DayOne is looking for companies with emerging technologies for pain treatment as well as digital healthcare solutions in pain management.
The DayOne Accelerator is the healthcare innovation initiative of Basel Area Business & Innovation and is split into three categories: Digital Health, Tech and Innovation Booster. They support promising new digital health and precision medicine ventures with guidance, mentorship, funding and collaborative workspaces. From 2018, DayOne has supported 20 companies with a combined valuation of over CHF 65 million, contributing to the life sciences ecosystem of the Basel Area. DayOne has helped launch, connect and mentor a number of innovative healthcare ventures, which include companies such as Zoundream and Nutrix in addition to others in medtech, medical device, digital health, AI, nutrition, health monitoring, medical access and more.
Building on this success, the DayOne Accelerator is extending its offering – both in terms of content and the area it covers. Going forward, DayOne is opening its accelerator to startups operating in practically all areas of digital health. It will also expand its financial support to allow companies in the fields of prevention, diagnostics and treatment to apply for grants as well.
For the Digital Health track, three startups will be considered for the three-month funding program, with each in line to receive a grant of up to CHF 45,000 in funding and services in addition to expert coaching and access to the world leading biopharma ecosystem of the Basel Area.
"At DayOne, we believe that the future of health can only evolve if advances in medical and healthcare technologies go hand in hand with innovation across the ecosystem. Today innovation primarily takes place within separate silos, where pharmaceutical companies, healthcare providers and governments have different agendas. Bringing all these areas together in a neutral setting of collaboration is the key to shaping the future of health, building an innovation hub. We are delighted to launch these new calls to encourage innovation in digital health and support entrepreneurs realise their vision while providing much needed solutions for patients."
Lucas Scherdel, Director Healthcare Innovation – DayOne
DayOne is also announcing calls for its Tech and Innovation Booster verticals, with deadlines in Q1 2022. For the Tech vertical, the focus is on startups in medical robotics, 3D printing, virtual reality in healthcare applications and technological solutions for personalized medicine. The winners will receive financial support of up to CHF 100,000 in funding and services, amongst other benefits including offering of shared offices and access to a world leading medtech and microtechnology network.
Finally, the Innovation Booster category supports budding projects in the area of digital health. The focus here is on patient-centric solutions that have been jointly developed by startups in close collaboration with academic partners and Big Pharma. The Innovation Booster category is operated on a nationwide basis, with startups able to submit applications in the first quarter of 2022.
In addition to financing support, DayOne helps build out companies and teams from inception to a point where they can raise financing and enter strategic collaborations. Harnessing the Basel Area's unique position as a global healthcare hub, as well as its rising popularity among investors, DayOne is looking to attract the next generation of breakthrough companies. Interested groups can find information at www.dayone.swiss/digitalhealth.
DayOne accelerates innovative ventures across three verticals:
Digital Health: Pain management track starts Jan 2022 – apply by Nov 5, 2021
Tech: Ventures in medical robotics, virtual reality for healthcare or personalized medical technologies – call opens Q1 2022
Innovation Booster: Empowered by Innosuisse, with a special focus on the interface with big pharma and academia – call opens Q1 2022
About DayOne Accelerator
At DayOne, we are shaping the future of health by accelerating digital transformation in Europe's leading healthcare and life sciences hub. As the Healthcare Innovation initiative by Basel Area Business & Innovation, DayOne believes in a patient-centric and sustainable approach to healthcare. Led by a team of industry experts, medical doctors, tech enthusiasts and researchers, the DayOne innovation hub serves a growing community of 2,000+ healthcare innovators throughout the Basel Area life sciences and healthcare ecosystem. The DayOne Accelerator boosts innovative ventures that combine groundbreaking technologies, healthcare expertise, and entrepreneurial spirit. Since 2018, the DayOne Accelerator has supported 20 companies, with a combined valuation of over CHF 65 million.
About Basel Area Business & Innovation
Basel Area Business & Innovation is the investment and innovation promotion agency dedicated to helping companies, institutions and startups find business success in the Basel Area, Switzerland. The organization targets and attracts companies to settle, supports founders of innovative ventures, and drives high growth initiatives in order to establish the region as the Swiss business and innovation hub of the future. The non-profit agency focuses on growing the area's cutting-edge industries life sciences, healthcare and production technologies.
Sonasoft | August 19, 2021
Sonasoft Corp. (OTCQB: SSFT) has executed a strategic partnership with Information Visibility Technology (IVT), a pioneer in healthcare information technologies. IVT will be leveraging Sonasoft’s AI engine, SAIBRE, to uncover key business insights and intelligence. “This is a great fit for our new SAIBRE AI engine,” says Mike Khanna, Sonasoft’s CEO. “IVT’s expert domain knowledge combined with SAIBRE brings a new approach, allowing us to rapidly prototype and deploy cost saving solutions to the healthcare space.”
IVT and Sonasoft will initially collaborate on deploying two AI bots to reduce the inflexibility often found in healthcare solutions. These include an inventory management bot for supply and demand forecasting and a dynamic pricing bot to move away from contract pricing, which dominates today’s healthcare industry.
“Our partnership with Sonasoft creates an ideal approach to solving supply chain and distribution issues that are endemic in the industry and exacerbated by the ongoing pandemic,” says Chris Shaw, co-founder at IVT. “Combining our knowledge and experience in healthcare and data analytics will provide deep visibility which will lead to significant cost reductions for our customers in a highly competitive marketplace.”
Prescryptive Health and Bartell Drugs | May 08, 2020
Prescryptive Health and Bartell Drugs announced today a partnership to expand access to reliable and secure COVID-19 antibody testing.
This coalition will operate under the directive of the Department of Health and Human Services.
Once the program is launched, eligible employees will be able to use their mobile phone to register for a test, select a pharmacy testing location and schedule an appointment.
Prescryptive Health, a healthcare technology company headquartered in Redmond, WA, and Bartell Drugs, the Seattle-based drug store chain, announced today a partnership to expand access to reliable and secure COVID-19 antibody testing. This coalition will operate under the directive of the Department of Health and Human Services by allowing licensed pharmacists to order and administer FDA-authorized COVID-19 antibody tests.
As tests are made available, pharmacists will be instrumental in the administration of safe, reliable and accurate COVID-19 tests, Pharmacists are trusted and valued healthcare professionals who play a critical role in our community's management of and recovery from this crisis. We are proud to be in partnership with Bartell Drugs to deploy a platform to accelerate testing that preserves patient privacy.
- Chris Blackley, CEO of Prescryptive Health.
Read More: DOXIMITY LAUNCHES DOXIMITY DIALER VIDEO- A FREE TELEHEALTH APP FOR PROVIDERS
Widespread, verifiable COVID-19 testing is essential to accelerate the nation's return to work, hasten our economic recovery and keep our country safe. In its initial phase, the program will offer employers and consumers access to serologic antibody tests which signify that a person may have been exposed to COVID-19 and developed a potential immune response. The tests will soon be available at select Bartell Drugs locations.
Supporting and investing in our communities is an integral part of what Bartell's stands for, we are proud to partner with Prescryptive in this coalition designed to drive convenient, widespread availability of reliable and safe testing. Our goal is to help accelerate the return of healthy individuals to the workplace to get our community back on its feet.
- Billy Chow, VP of Pharmacy at Bartell's.
The program is built on Prescryptive's blockchain-encrypted prescription intelligence platform. Employers will have the option to enroll their employees to be tested at participating Bartell's pharmacies. Once the program is launched, eligible employees who have been enrolled will be able to use their mobile phone to register for a test, select a pharmacy testing location and schedule an appointment.
Read More: FITBIT LAUNCHED A LARGE-SCALE STUDY TO VALIDATE ITS TECHNOLOGY TO DETECT ATRIAL FIBRILLATION
After they are tested, individuals will receive a private and secure digital certificate of the test results, validating that the test was administered by a licensed healthcare professional. Discounted tests and scheduling priority will be provided to healthcare professionals, healthcare workers and high-risk individuals.
About Prescryptive Health
Prescryptive is putting an end to the U.S. drug debacle with the world's first prescription intelligence platform, eliminating middlemen from the drug market to let consumers take charge of their medication costs. By delivering a simple, mobile experience that integrates in real-time with their benefit plan and provider, we are transforming the prescription drug market by empowering consumers, cutting costs, and inspiring better health. To learn more about how we're rewriting the script, visit www.prescryptive.com.
About Bartell Drugs
Bartell Drugs is operating 67 locations in King, Snohomish and Pierce counties and serving the Northwest since 1890, locally owned Bartell Drugs is dedicated to providing extraordinary service that advances health, happiness and wellbeing. For more information on Bartell Drugs, visit www.bartelldrugs.com.